Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

Summary

This phase I trial tests the safety, side effects, and best dose of tegavivint in treating patients with large b-cell lymphomas that has come back (relapsed) or does not respond to treatment (refractory). Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tegavivint may help control the disease.

Timeline

Start

2023-03-06

Primary completion

2028-03-05

Completion

2028-03-05

Drugs

Indications